BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues.

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

TIACCI, Enrico;DE CAROLIS, LUCA;FALZETTI, Franca;ASCANI, Stefano;CAPPONI, Monia;MARTELLI, Maria Paola;FALINI, Brunangelo;
2015

Abstract

BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues.
2015
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/1366188
Citazioni
  • ???jsp.display-item.citation.pmc??? 117
  • Scopus 263
  • ???jsp.display-item.citation.isi??? 230
social impact